Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

IMMUNESTRATIFY

IMMUNESTRATIFY The molecular immune signature in ME/CFS as stratification tool for future personalized treatment

Background

About the study

ME/CFS is a disease where people can have very different symptoms, suggesting that there might be multiple subtypes of the disease. The researchers will answer two main questions:

  1. Can patients with ME/CFS be classified into subgroups based on immune signatures? The researchers will investigate whether classification using previously identified immune signatures that occur in patients with other disease states (who also experience severe fatigue) can be done. And can specific symptoms be linked to these immune signatures?
  2. Are immune cells of ME/CFS patients hypersensitive to stimuli and does this result in pathogenic inflammatory substances?

For this project blood samples from the people with ME/CFS from the NMCB will be studied. This project aims to improve our understanding on the role of the immune system in ME/CFS and provide clues for the development of new treatments. The immune signatures detected in ME/CFS patients will be made available as a diagnostic test.

Subproject

Team

Bart Humer

Bart Humer

PhD Student

Wim Dik

Dr. Wim Dik

Laboratory specialist in medical immunology

Dr. Marjan Versnel

Principal investigator